41 results about "Neurocognitive Disturbance" patented technology

A user-friendly reliable process is provided to help diagnose (assess) and treat (rehabilitate) impairment or deficiencies in a person (subject or patient) caused by a traumatic brain injury (TBI) or other neurocognitive disorders. The economical, safe, effective process can include: generating and electronically displaying a virtual reality environment (VRE) with moveable images; identifying and letting the TBI person perform a task in the VRE; electronically inputting and recording the performance data with an electronic interactive communications device; electronically evaluating the person's performance and assessing the person's impairment by electronically determining a deficiency in the person's cognitive function (e.g. memory, recall, recognition, attention, spatial awareness) and/or motor function (i.e. motor skills, e.g. balance) as a result of the TBI or other neurocognitive disorder.

The invention belongs to the medicine field and provides a borneol-curcumin liposome, a preparation method of the borneol-curcumin liposome and an application of the borneol-curcumin liposome in preparing medicines for preventing human immunodeficiency virus-1(HIV-1) associated neurocognitive disorder. The borneol-curcumin liposome is prepared by, by mass, 270-330 parts of lecithin, 90-110 parts of cholesterol, 0.9-1.1 parts of curcumin and 0.09-0.11 part of borneol. The preparation method includes that the components and 0-11 parts by mass of oxidation protection agents are dissolved by absolute ethyl alcohol, a mixture is subjected to rotary evaporating on a rotary evaporator until ethanol is volatilized to form uniform films, a defined amount of phosphate buffer solution is added, the incubation is performed for three hours, a hydration reaction is undertaken to form an emulsion, then the ultrasound is performed for 10 minutes, and the emulsion passes through a 0.45 micrometer millipore filter to obtain uniform particles so that the borneol-curcumin liposome is obtained. The borneol-curcumin liposome can be prepared to various dosage forms of HIV-associated neurocognitive disorder (HAND) resistant medicines which are peroral, and the pertinence of the borneol-curcumin liposome for treating HAND is high, and the effect is good.

A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.

Provided are wearable systems and methods for treatment of a neurocognitive impairment, disease or disorder in a patient in need thereof comprising a visual field occluder useful, for example, in prism adaptation therapy.

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

A method and composition for suppressing replication of the HIV-1 virus strains, modulating the production and liberation of inflammatory mediators; and the prevention and treatment of neurocognitive disorders. The method comprises administering to a subject an effective amount of an a macrocyclic diterpenoid, such as 4R cembranoid.

The invention relates to compounds of the following formula: